Back to Oncology
Oncologyv2008_originalEvidence-Based

Khorana Risk Score for Venous Thromboembolism in Cancer Patients

Predicts VTE risk for cancer patients depending on cancer type and other factors. This validated risk assessment tool helps identify cancer patients at high risk for venous thromboembolism who may benefit from thromboprophylaxis during chemotherapy treatment.

Clinical Input Parameters

Clinical Assessment
Awaiting Parameters
risk score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Khorana Risk Score for Venous Thromboembolism in Cancer Patients is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within oncology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Cancer type (very high-risk: 2 pts, high-risk: 1 pt, standard: 0 pts) + platelet count ≥350 (1 pt) + Hgb <10 or EPO use (1 pt) + leukocyte count >11 (1 pt) + BMI ≥35 (1 pt)

Clinical Pearls & Practice Notes

  • Developed for cancer patients starting chemotherapy (solid tumors and lymphomas)
  • Do NOT use in patients with brain tumors or multiple myeloma
  • Not intended for diagnosing VTE but for predicting future risk
  • Original high-risk cutoff: ≥3 points; recent evidence suggests ≥2 points may be more optimal
  • VTE incidence at 6 months: Low risk (0 pts): 5.0%, Intermediate risk (1-2 pts): 6.6%, High risk (≥3 pts): 11.0%
  • High-risk patients may benefit from thromboprophylaxis with LMWH (64% VTE risk reduction)
  • Limited sensitivity: only 23.4% of patients who develop VTE are classified as high risk
  • Performance varies by cancer type; less predictive in lung cancer patients
  • Very high-risk cancers: stomach, pancreas
  • High-risk cancers: lung, lymphoma, gynecologic, bladder, testicular

Evidence & Literature Citations

  1. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated venous thromboembolism. Blood. 2008;111(10):4902-7.
  2. Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116(24):5377-82.
  3. Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med. 2012;7(3):291-2.
  4. Mulder FI, Candeloro M, Kamphuisen PW, Di Nisio M, Bossuyt PM, Guman N, et al. The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. Haematologica. 2019;104(6):1277-1287.

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.